This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Aug 2019

Key Pharmaceuticals acquired by Lexon UK

Cambridgeshire based Key Pharmaceuticals, a specialist in development, licensing and support of innovative generics, has been acquired by the Lexon Group of companies.

The Lexon Group, which posted revenues of £300m last year, has activities ranging from wholesaling, to retail, to homecare.

With additional offices in Dublin and Pune, Key Pharmaceuticals has been involved in the development, manufacture and regulatory support of generic pharmaceuticals for 20 years. Key recently celebrated their 25th generic drug launch in the UK with Lamzarin (Gliclazide XR).

Their products are now being prescribed across the country and delivered to hospitals, clinics and pharmacies up and down the UK. Given their products are all manufactured to UK MHRA GMP standards, they have also been able to successfully outlicense and supply to markets across all 6 continents.

Key also offers project management of drug development through the whole product lifecycle to those who require it. This includes formulation, development, clinical, manufacturing scale up, registration and ongoing pharmacovigilance support.

Tushar Patel, Technical Director of Key Pharmaceuticals, had this to say: “I’m proud of what we have achieved so far over the course of 20 years. With additional support provided by the Lexon Group, I’m certain that the next 20 years will be even more exciting.”

Mentioned Companies
Key Pharmaceuticals Ltd
View company profile